|
|
|
|
Mylan Strengthens Portfolio With Generic Diabetes Drugs
Mylan Inc.(MYL) has entered into an agreement with Takeda Pharmaceutical for two type II diabetes drugs Actoplus Met and Actos, which recorded 2009 sales of $459 million and $3.4 billion, respectively. Following the agreement, Mylan will be able to launch...
|
|
|
Mylan Strengthens Portfolio - Analyst Blog
Mylan Inc.( MYL ) has entered into an agreement with Takeda Pharmaceutical for two type II diabetes drugs Actoplus Met and Actos, which recorded 2009 sales of $459 million and $3.4 billion, respectively. Following the agreement, Mylan will be able to...
|
|
|
Lipid Increases Due to Antiretroviral Therapy May Promote Hepatitis C Virus Replication
Susanna Naggie form Duke University Medical Center and colleagues conducted a pilot study to assess the impact of ART-induced lipid changes on HCV pathogenesis in.HIV/HCV coinfected individuals tend to experience more rapid liver disease progression than...
|
|
|
Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients
Campo RE et al.Both regimens were associated with low virological failure rates and significant improvements in treatment satisfaction, adherence and QoL after switching from PIbased therapy, with no differences between regimens. Switch from protease...
|
|
|
Erratum: Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry
_ Erratum: Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry.
|
|
|
Prevalence (59%) and Correlates of Minor Neurocognitive Disorders in Asymptomatic HIV-infected Outpatients
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 Reported by Jules Levin CROI 2010 Feb 16-19 SF Nicoletta Ciccarelli1,2, Massimiliano Fabbiani1, Simona Di Giambenedetto1, Iuri Fanti1, Manuela Colafigli1,...
|
|
|
Short-Term Raltegravir Monotherapy Does Not Predispose Patients to Develop RAL Resistance During Subsequent Co
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 Reported by Jules Levin CROI 2010 Feb 16-19 SF Michael D.Miller, Richard J.O. Barnard, Marc Witmer, Jing Zhao, Bach-Yen Nguyen, Hedy Teppler, and Daria...
|
|
|
Hepatic Safety & Efficacy of Raltegravir in Patients Co-infected with HIV and Hepatitis B (HBV) and/or C (HCV)
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 Reported by Jules Levin CROI 2010 Feb 16-19 SF Jurgen Rockstroh1, Hedy Teppler2, Jing Zhao2, Peter Sklar2, Charlotte Harvey2, Randi Leavitt2, and Bach-Yen...
|
|
|
Population-based Sequencing of the V3-loop is Comparable to the Enhanced Sensitivity Trofile Assay (ESTA) in P
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 Reported by jules Levin 17th CROI 2010 Feb 16-19 SF RA McGovern, W Dong, X Zhong, T Mo, D Knapp, A Thielen, D Chapman, M Lewis, I James, J Heera H Valdez, PR...
|
|
|
Large-Scale Application of 'Deep' Sequencing Using 454 Technology to HIV Tropism Screening
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 Reported by Jules Levin 17th CROI 2010 Feb 16-19 SF Luke C Swenson1, Winnie Dong1, Theresa Mo1, Alexander Thielen2, Mark Jensen3, Doug Chapman4, Ian James5,...
|
|
|
Modest Lipid and Body Fat Changes With Raltegravir vs Efavirenz in 96-Week Trial
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 17th Conference on Retroviruses and Opportunistic Infections, February 16-19, 2010, San Francisco Mark Mascolini Both raltegravir and efavirenz had a...
|
|
|
Standard First Regimens Less Effective in US Blacks Than Others
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 17th Conference on Retroviruses and Opportunistic Infections, February 16-19, 2010, San Francisco Mark Mascolini African Americans had about a twice higher...
|
|
|
Combinations of Mutations in the Connection Domain of Human Immunodeficiency Virus Type 1 Reverse Transcriptas
Soumi Gupta*, Signe Fransen, Ellen E Paxinos, Eric Stawiski, Wei Huang, and Christos J Petropoulos Monogram Biosciences, South San Francisco, CA 94080 * To whom correspondence should be addressed.Email: sgupta{at}monogrambio.com. Recent reports have...
|
|
|
Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 Infection
Cooper DA et al.Twicedaily maraviroc was not noninferior to efavirenz at 50 copies/mL in the primary analysis. However, 15% of patients would have been ineligible for inclusion by a more sensitive screening assay. Maraviroc versus Efavirenz,...
|
|
|
ACTG 5202 Sub-study Finds Lipoatrophy Uncommon, Antiretroviral Drugs Have Varying Effects on Bone and Body Fat
ACTG 5224s, a sub-study of the larger ACTG 5202 trial, looked at 2 types of body composition changes associated with antiretroviral therapy, bone loss and.ACTG 5202 was a randomized Phase 3b clinical trial comparing the effectiveness of commonly used ART...
|
|
|
HIV/AIDS - Scientists at Harvard University release new data on HIV/AIDS
Learn more about a six-week, no-risk free trial of AIDS Weekly We're a pay-per-view site for premium content.If you'd like to purchase this article, it's only $3.00. According to a study from the United States, 'National initiatives offering non-nucleoside...
|
|
|
Stage-Dependent Inhibition of HIV-1 Replication by Antiretroviral Drugs in Cell Culture [Antiviral Agents]
Stage-Dependent Inhibition of HIV-1 Replication by Antiretroviral Drugs in Cell Culture Daniel A.Donahue,1,2 Richard D. Sloan,1 Bjrn D. Kuhl,1,3 Tamara Bar-Magen,1 Susan M. Schader,1,2 and Mark A. Wainberg1,2,3* McGill University AIDS Centre, Lady...
|
|
|
The Future of First-Line HIV Treatment: Are Atripla's Days as King Numbered?
A Blog Entry From CROI 2010 Atripla (which is a combination of efavirenz + tenofovir + emtricitabine) is the acknowledged king in the realm of first-line antiretroviral therapy.long_space Le Roi est mort, vive le Roi!long_space Not so fast: The king still...
|
|
|
Elvucitabine Versus 3TC in First-Line Regimens for 96 Weeks - see slides from poster below
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 17th Conference on Retroviruses and Opportunistic Infections, February 16-19, 2010, San Francisco Mark Mascolini Elvucitabine, a cytosine nucleoside analog,...
|
|
|
When to Start Antiretroviral Therapy in HIV-Infected Patients with Tuberculosis?
Trial results from South Africa demonstrate unequivocally that coinfected patients should start antiretroviral therapy no more than 4 weeks after completing the intensive phase of tuberculosis therapy.Whether earlier initiation leads to better outcomes...
|
|
|
Bone & Limb Fat Outcomes in ACTG5202- More Bone Loss With TDF/FTC Than ABC/3TC
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 17th Conference on Retroviruses and Opportunistic Infections, February 16-19, 2010, San Francisco Mark Mascolini 'All regimens appeared to produce an initial...
|
|
|
Cayston Nod a Small Win for Gilead Ahead of New HIV Data
Gilead Sciences Inc.'s ongoing strategy to diversify its pipeline scored a small victory with the approval of inhaled aztreonam lysine drug Cayston, but there's no question the firm's future growth still hinges largely on its next-generation HIV pipeline.
|
|
|
Single Pill Antiretroviral Therapy Improves Adherence in Difficult-to-Treat Populations: Presented at CROI
-- A fixed-dose combination antiretroviral pill improves adherence to treatment regimens among people with HIV, researchers said here at the 17th Conference on Retroviruses and Opportunistic Infections (CROI).'In a difficult to treat population of patients...
|
|
|
Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095
Schouten JT et al.In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy.
|
|
|
Newer HIV Antiretroviral Regimens Produce Few Cases of Lipoatrophy: Presented at CROI
my personal edition> aids and hiv > news E-Mail this DGDispatch to a colleague DGDispatch SAN FRANCISCO -- February 21, 2010 -- Long-term treatment of HIV with regimens anchored by the non-nucleoside reverse transcriptase efavirenz or the...
|
